Luye Pharma Group, Ltd.

Industry

  • Pharmaceuticals
    • Drug Delivery
      • Transdermal
    • Specialty Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Digital Health
    • Disease Management

Other Names/Subsidiaries

  • A-Bio Pharma
  • Beijing WBL Peking University Biotech
  • Guangzhou Patronus Biotech
  • Jimai Biological Technology
  • Luye Biotech
  • Luye Pharma
  • Nanjing Luye Sike Pharmaceutical
  • Shandong Boan Biological Technology
  • Shandong Boan Biotechnology
  • Shandong Luye Pharmaceutical
  • Sichuan Baoguang
  • Sichuan Luye Baoguang Pharmaceutical Industry
  • Solid Success Holdings
  • Vela Diagnostics
  • Yantai Patronus Biotech
See more in Biomedtracker

Latest on Luye Pharma Group, Ltd.

Scrip

Strong Sales, Deals Propel China Biotechs To 2023 Profitability

 
• By Dexter Jie Yan

Shanghai Henlius Biotech Co. Ltd. and Shanghai Allist Pharmaceuticals Co., Ltd. led the group of Chinese biotech companies reporting full-year net profits in 2023, boosting confidence in the growin

Scrip

Enzene CEO On Biosimilar Denosumab And Cetuximab; Medicare Negotiation Impact On US Market

 
• By Vibha Ravi

Enzene Biosciences, a subsidiary of Alkem Laboratories Ltd , plans a regulatory filing in the US for a biosimilar to Amgen, Inc. ’s blockbuster osteoporosis drug Prolia (denosumab). Having tied up w

Generics Bulletin

Boan Biotech Begins International Phase III Trial Of Denosumab Biosimilars

 
• By Chloe Kent

Following the approval of its Prolia (denosumab) biosimilar in China late last year, Luye Pharma Group, Ltd. subsidiary Boan Biotech has now enrolled the first subject in an international multi-cent

Generics Bulletin

With Prolia Rival In The Bag, China’s Luye Takes Aim At Xgeva Biosimilar

 
• By Dean Rudge

China’s regulator has accepted for review local firm Boan Biotech’s biologics license application for its proposed biosimilar to Amgen’s Xgeva (denosumab) – months after the Luye Pharma Group, Ltd.